Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 253

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 253
---
 following table sets forth selected consolidated statements of income (loss) data for each of the periods indicated:

    For the Year Ended December 31,

    2024

    2023

    Change

    Change

    (in thousands, except per share amounts)

    $

    %

    Revenues:

    Products, net
     
    $
    1,787,960

    $
    1,144,876

    $
    643,084

    56
    %

    Collaboration and other

    114,019

    98,460

    15,559

    16
    %

    Total revenues

    1,901,979

    1,243,336

    658,643

    53
    %

    Cost and expenses:

    Cost of sales (excluding amortization of in-licensed rights)

    319,099

    150,343

    168,756

    112
    %

    Research and development

    804,522

    877,387

    (72,865
    )

    (8
    )%

    Selling, general and administrative

    557,872

    481,871

    76,001

    16
    %

    Amortization of in-licensed rights

    2,405

    1,559

    846

    54
    %

    Total cost and expenses

    1,683,898

    1,511,160

    172,738

    11
    %

    Operating income (loss)

    218,081

    (267,824
    )

    485,905

    NM*

    Other income (loss), net:

    Other income, net

    42,693

    33,055

    9,638

    29
    %

    Loss on debt extinguishment

    —

    (387,329
    )

    387,329

    (100
    )%

    Gain from sale of Priority Review Voucher

    —

    102,000

    (102,000
    )

    (100
    )%

    Total other income (loss), net

    42,693

    (252,274
    )

    294,967

    NM*

    Income (loss) before income tax expense

    260